Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year
2021 marked Mydecine’s patent application for its MYCO-003 drug candidateIt also marked notable clinical trials on various aspects, including smoking cessationMydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeuticsThese milestones have laid down the groundwork, not just for Q3 of the 2021 financial year but also for the company’s growth in the 2022 calendar…